Communicated by Jean-Marie Lehn, June 1, 1993 (received for review March 8, 1993) ABSTRACT Transient global forebrain ischemia induces in rat brain a large increase of expression of the immediate early genes c-fos and c-jun and of the mRNAs for the 70-kDa heat-shock protein and for the form of the amyloid ,-protein precursor including the Kunitz-type protease-inhibitor domain. At 24 hr after ischemia, this increased expression is particularly observed in regions that are vulnerable to the deleterious effects of ischemia, such as pyramidal cells of the CAl field in the hippocampus. In an attempt to find conditions which prevent the deleterious effects of ischemia, representatives of three different classes of K+ channel openers, (-)-cromakalim, nicorandil, and pinacidil, were administered both before ischemia and during the reperfusion period. This treatment totally blocked the ischemia-induced expression of the different genes. In addition it markedly protected neuronal cells against degeneration. The mechanism of the neuroprotective effects involves the opening of ATP-sensitive K+ channels since glipizide, a specific blocker of that type of channel, abolished the beneficial effects of K+ channel openers. The various classes of K+ channel openers seem to deserve attention as potential drugs for cerebral ischemia.
Global forebrain ischemia leads to a complete neuronal death in the CAl field of the hippocampus after 7 days of recovery, whereas the adjacent CA3 sector and the dentate gyrus are largely more resistant (1, 2) . The main factors involved in the damage of neuronal tissue following ischemia are ATP depletion (3) , intracellular acidosis (4) , enhanced release and/or diminished reuptake of the excitatory transmitters glutamate and aspartate (5) , generation of free radicals (6) , and increased Ca2+ influx and K+ efflux (7, 8) .
N-Methyl-D-aspartate (NMDA) antagonists and Ca2+ channel blockers have exhibited little ability to reduce tissue damage in animals with global ischemia (7, 9) . They seem to be more helpful in focal ischemia (10, 11) . Until now antagonists of a-amino-3-hydroxy-5-methylisoxazolepropionate have been considered as the best neuroprotective agents against global brain injury (12, 13) . A new class of drugs has recently attracted considerable interest for protection of the ischemic heart. This is the family of ATP-sensitive K+ channel (KATP channel) openers (KCOs). These molecules, including (-)-cromakalim, pinacidil, nicorandil, and RP 49356, are potent vasorelaxant and cardioprotective agents (for reviews see refs. [14] [15] [16] . The cardioprotective effects of these drugs are completely reversed by antidiabetic sulfonylureas such as glibenclamide, which are blockers of KATP channels (17, 18) .
KATP channels are present in the brain (19) (20) (21) and are particularly abundant in hippocampal structures, known to be vulnerable to the deleterious effects of ischemia. These channels are activated by the same KCOs that activate cardiac KATP channels (22) . Therefore it appeared worthwhile to analyze whether the KCOs can prevent the expression of the immediate early genes c-fos and c-jun and the genes encoding the 70-kDa heat-shock protein (HSP7O) and amyloid p-protein precursor (APP), which are induced following global cerebral ischemia (23) (24) (25) (26) (27) (28) (29) (30) , and to determine more directly whether KCOs are neuroprotective.
MATERIALS AND METHODS
Animals. Experiments were performed on 10-to 12-weekold, 250-to 300-g male Wistar rats (Charles River Breeding Laboratories).
Drug Treatments. (-)-Cromakalim was from Beecham Pharmaceuticals, pinacidil from Leo Pharmaceuticals, and nicorandil from Rhone-Poulenc Rorer. KCOs (10 nmol/5 ,ul)
were administered intracerebroventricularly 30 min before the induction of cerebral ischemia and once each day during the recovery period. These doses of KCOs are similar to those previously shown to prevent seizures (31) . Glipizide (1 ttmol/5 ul; Pfizer Diagnostics) was injected intracerebroventricularly 20 min prior to openers. Control experiments were performed with intracerebroventricular injection of 0.9% NaCl under conditions used for openers.
Cerebral Ischemia Model. Forebrain ischemia involved occlusion of all four major extracranial arteries ("four-vessel occlusion" model) (2) .
The first day, the rats were anesthesized by inhalation of 2% halothane mixed with 30% oxygen/70% nitrous oxide. Body temperature was maintained at 37°C. The vertebral arteries were irreversibly occluded by electrocoagulation. After a delay of 1 day for recovery, both common carotid arteries were clamped during 20 min in awake and spontaneously ventilating animals. Rats lost their righting reflex within 1 min of carotid clamping. Pharmacological treatments were administered 30 min prior to forebrain ischemia by an injection needle that was lowered bilaterally into the lateral ventricle. The injection needle was connected to a Hamilton syringe (10 ,l) 
RESULTS
Levels of c-fos and c-jun mRNAs and of the transcriptional regulatory factors they encode, Fos and Jun, are highly increased in rat and gerbil brain following global and focal ischemia or traumatic brain injury (23) (24) (25) . Fig. 1 B-F shows the regional expression of c-fos and c-jun mRNAs in the rat hippocampus at various times of recovery following a 20-min ischemic insult. The general expression of the two probes was identical. No induction was observed in hippocampal cells of sham-control animals (Fig. 1A) . The increase in c-fos and c-jun mRNAs within the dentate granule cells was first observed after 1 hr, was more pronounced at 6 hr, and had disappeared at 24 hr following ischemia. High c-fos and c-jun labeling was observed in CA3 and CAl Injections of (-)-cromakalim (10 nmol) before the start of cerebral ischemia and during the days of recovery totally blocked the induction of ischemia-induced expression ofboth c-fos ( Fig. 1 G-I ) and c-jun (data not shown). When the drug was administered just before ischemic injury but not during reperfusion, the hybridization signal appeared at 24 hr of recovery (Fig. 1J) . Like (-)-cromakalim injections, nicorandil and pinacidil injections (10 nmol) prevented the increase of both immediate early genes following global ischemia (data not shown).
HSPs play an important role in the response to stressful conditions of various cell types (for a review see ref. 38 ). Induction of the synthesis of HSP70 was previously observed in ischemia (26, 27) . Fig. 2 (Fig. 2J) .
The three isoforms of APP-APP695, APP751, and APP770-are derived from alternative splicing of a single gene (35) . Alterations of APP expression have previously been observed following ischemia (28, 29) . Fig. 3 shows the expression of APP695 (B-D) and APP751 (F-H) mRNAs in the rat hippocampus following a 20-min ischemic insult. Unlike APP751 mRNA, which was absent in hippocampus of sham-operated rats (Fig. 3F) , APP695 mRNA was abundant in the granular layer of dentate gyrus and in pyramidal cells in layers CAl through CA3 ofcontrol rat (Fig.  3A) . The expression of APP695 mRNA did not change after global ischemia and recovery for 7 days (Fig. 3 B-D) . Pretreatment with KCOs such as pinacidil had no effect (Fig.  3E) . Conversely, APP751 mRNA, which encodes the Kunitztype protease-inhibitor domain, was induced at 24 hr postischemia (Fig. 3H) , as previously described (39) , peaked at 3 days (data not shown), and remained elevated until 7 days (Fig. 31) . KCOs such as pinacidil blocked the induction of APP751 following global ischemia (Fig. 3J) . Fig. 4 shows more directly the neuroprotective effects of KCOs by following the appearance of peripheral-type benzo- diazepine binding sites, which are associated with reactive astroglia and macrophage invasion following an ischemic insult and which provide an excellent marker of neuronal degeneration (36) . After an ischemic insult of20 min and 7 days of recovery, an increase in [3H]PK 11195 labeling was particularly observed in the pyramidal-cell layer ofthe CAl field and the hilus (Fig. 4 B and D) . Pretreatment with (-)-cromakalim reduced the ischemia-induced increase of [3H]PK 11195 binding and thus protected against ischemia-induced loss of CAl pyramidal cells (Fig. 4 C and D) . Counting of intact cells and density of neurons on histologic sections showed that delayed neuronal death was observed in 78% of CAl neurons 7 days after ischemia and that 65% ofthe CAl cells survived at 7 days of reperfusion after KCO treatment.
Since the sulfonylurea glipizide is a potent blocker of KATP channels after they have been activated by KCOs (22), we analyzed the effect of glipizide on the protection provided by (-)-cromakalim. For each probe used (c-fos, c-jun, HSP70, APP), glipizide completely antagonized the effect of KCOs on the induction of expression following ischemic injury. Fig.  5A shows that a hippocampal expression of HSP70 mRNA could be induced, as in the control (Fig. 2B ), 1 hr after ischemia if glipizide had been injected prior to (-)-cromakalim (before ischemia), whereas, as previously observed, HSP70 induction was totally prevented by injection of the KCO alone (Fig. 5B) . (A-C) Sections were obtained from saline-treated rats in sham control (A) and 7 days after a 20-min ischemia and from a (-)-cromakalim-pretreated rat 7 days after ischemia (C [14] [15] [16] . Their action is associated with a shortening of the cardiac action potential that (i) prevents Ca2+ entry that would normally occur during the plateau phase and, (ii) consequently, decreases the consumption of ATP which is necessary in normal conditions for the various Ca2+ pumps in charge of maintaining a low intracellular Ca2+ concentration. Saving ATP and preventing excessive Ca2+ entry are two important properties for potential drugs in the treatment of cardiac ischemia. It is therefore not surprising that (-)-cromakalim, pinacidil, and RP 52891 are capable of reducing ischemic injury (41) .
KATP channels are present in the brain (19) (20) (21) with high density in substantia nigra, globus pallidus, cerebellum, and hippocampus. They are sensitive to external concentrations of glucose (42) and are opened by anoxia (20, 22, 43) . They are also opened by KCOs (22) . They are present in hippocampus both presynaptically and postsynaptically (44) (45) (46) (47) and are particularly situated in mossy fibers which are associated with glutamate release (48) .
Brain ischemia is associated with an excessive extracellular level of glutamate (5), probably mainly due to the fact that the high intracellular Na+ concentration produced by ischemia prevents glutamate reuptake (after it has been liberated) through the glutamate-Na+ cotransporter (49) . On the other hand, an important extracellular glutamate concentration will produce a strong stimulation of NMDA receptors and an increased Ca2+ entry into target neurons that will be responsible for neuronal death (5, 7) .
Two important properties can be expected from KCOs: (i) they should hyperpolarize synaptic terminals and thus massively prevent Ca2+ entry and consequently glutamate release (22, 42, 46) and (ii) they should hyperpolarize glutamate-sensitive neurons, thus conferring resistance to the depolarization induced by the various glutamate receptors and preventing the relief of the Mg2+ block of the NMDA receptor channel, which is known to be voltage-dependent and facilitated by a depolarization (50) . For all these reasons KCOs should be expected to have a protective action against ischemia.
The deleterious effects of ischemia are associated with the induction of expression of mRNAs encoding the Fos and Jun nuclear proteins (23) (24) (25) . Forebrain global ischemia produced an induction of these immediate early genes which at 24 hr postischemia remained intense only in the hippocampal CAl field.
HSPs, and particularly HSP70, are synthesized in a variety of stress-related conditions, including transient ischemia (26, 27 Many studies have shown the expression of APP following injuries of the central nervous system (28, 29, 51) . One of the APP forms is APP751, which contains a 56-amino acid domain very homologous to the Kunitz family of serine protease inhibitors (51) . The other molecular form, APP695, which derives from alternative splicing of the APP gene, does not contain this Kunitz inhibitor-like domain (35) . The transcriptional expression of APP695 was not affected by ischemia, whereas the level of mRNA for APP751 was greatly increased 24 hr after ischemia, as also was observed by Northern blot analyses (39) . This increase occurred in granule cells of the dentate gyrus and in pyramidal cells of CAl and CA3 fields and it persisted in the CAl region until 7 days after ischemia. Pinacidil injected before ischemia clearly blocked the expression of APP751.
All these results taken together show that the different types of KCOs prevent the ischemia-induced expression of very different genes. They are in complete agreement with results involving cell counting in the CAl sector or [3H]PK 11195 as a marker of cell death (36) .
One of the important properties of KATP channels is that, once they have been opened (e.g., by KCOs), they can be blocked with high potency by sulfonylureas such as glibenclamide or glipizide (17, 18, 22, 40, 42, 47, 52, 53) . Indeed the beneficial effects of KCOs against the series of events produced by ischemia were suppressed when openers were administered in the presence ofglipizide before ischemia was started.
In conclusion, this work shows beneficial effects of KCOs against global ischemia, as previously suggested (22) . These effects are due to the action of these different compounds on KATP channels (probably at both pre-and postsynaptic levels). To find a practical application for these observations in drug therapy, it will be necessary (i) to synthesize KCOs which pass the blood-brain barrier and (ii) to develop openers with an increased specificity for brain KATP channels, to avoid effects of these compounds on blood pressure. This seems to be feasible, since KATP channels in brain and in vascular smooth muscle belong to different subtypes (54) . Moreover, it is probable that KCOs will work better in hypoxic or ischemic than in normoxic conditions, since their action is known to be facilitated in the presence of ADP (52, 55) .
The mechanisms by which KCOs prevent the deleterious effects of ischemia are probably similar to those which make them potentially useful compounds against various types of epileptic seizures (31, 56) . Because this class of compounds prevents the expression of mRNAs related to APP, it might be interesting to investigate whether they would also be useful in preventing the development of amyloid accumulation in Alzheimer disease itself.
